Spinogenix Reports Positive Data on Alzheimer's Patients Who Continued Treatment With Tazbentetol For Up To 84 Weeks
Tazbentetol, a First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Demonstrated Favorable Safety Profile and Durable Therapeutic Benefits Clinical Case Study Presented at AAIC Highlights Caregiver Report of Rapid Cognitive Improvement with Supporting Clinical Outcome...
Tazbentetol, a First-in-Class, Oral Synaptic Regenerative Investigational Therapy, Demonstrated Favorable Safety Profile and Durable Therapeutic Benefits Clinical Case Study Presented at AAIC Highlights Caregiver Report of Rapid Cognitive Improvement with Supporting Clinical Outcome...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.